Corona Remedies

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE02ZQ01018
  • NSEID: CORONA
  • BSEID: 544644
INR
1,639.00
38.55 (2.41%)
BSENSE

Mar 20

BSE+NSE Vol: 23.4 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

23.4 k (-50.66%) Volume

Shareholding (Dec 2025)

FII

1.84%

Held by 18 FIIs

DII

0.05%

Held by 10 DIIs

Promoter

69.00%

Why is Corona Remedies Ltd falling/rising?

17-Mar-2026

As of 16-Mar, the stock price of Corona Remedies Ltd is rising to 1,548.95, attributed to a trend reversal and increased investor participation. It has outperformed its sector and is positioned favorably above key moving averages, indicating positive sentiment.

As of 16-Mar, the stock price of Corona Remedies Ltd is rising, currently at 1,548.95, with a change of 12.95 (0.84%) upward. This increase can be attributed to several factors. Notably, the stock has experienced a trend reversal, gaining after three consecutive days of decline. Additionally, it has outperformed its sector by 1.96% today, indicating stronger performance relative to its peers.<BR><BR>Investor participation has also increased, as evidenced by a significant rise in delivery volume, which reached 34.35 k on 13 March, marking a 155% increase compared to the 5-day average. This heightened interest from investors suggests a positive sentiment towards the stock. Furthermore, the stock's current price is above the 50-day, 100-day, and 200-day moving averages, although it is below the 5-day and 20-day moving averages. This positioning indicates a generally favorable trend in the stock's performance.<BR><BR>Overall, the combination of a trend reversal, increased investor participation, and relative outperformance in the sector contributes to the rising stock price of Corona Remedies Ltd.

View full answer

Which are the latest news on Corona Remedies?

20-Mar-2026
No latest news for Corona Remedies found.

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 9,966 Cr (Small Cap)

stock-summary
P/E

50.00

stock-summary
Industry P/E

31

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.01

stock-summary
Return on Equity

24.61%

stock-summary
Price to Book

16.31

Revenue and Profits:
Net Sales:
342 Cr
(Quarterly Results - Dec 2025)
Net Profit:
41 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.21%
0%
19.21%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Corona Remedies for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

27-Feb-2026 | Source : BSE

Intimation of Schedule of Analyst / Investor Meeting

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

17-Feb-2026 | Source : BSE

Intimation of participation in Analyst / Investor Conference

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

10-Feb-2026 | Source : BSE

Transcript of Earnings Conference Call with Analyst / Investor on Financial Results for the third quarter and nine months ended December 31 2025

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
19.13
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.86
Tax Ratio
24.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.60%
ROCE (avg)
29.97%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
50
Industry P/E
31
Price to Book Value
16.55
EV to EBIT
49.39
EV to EBITDA
41.74
EV to Capital Employed
16.72
EV to Sales
8.37
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
33.85%
ROE (Latest)
24.61%

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Mildly Bearish
OBV
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 13 Schemes (6.38%)

FIIs

Held by 18 FIIs (1.84%)

Promoter with highest holding

Ankurbhai K Mehta (22.0%)

Highest Public shareholder

Sepia Investments Limited (19.76%)

Individual Investors Holdings

1.36%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "342.42",
          "val2": "361.13",
          "chgp": "-5.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "83.16",
          "val2": "78.47",
          "chgp": "5.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.66",
          "val2": "1.93",
          "chgp": "-13.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "41.25",
          "val2": "52.15",
          "chgp": "-20.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "24.29%",
          "val2": "21.73%",
          "chgp": "2.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Corona Remedies"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Corona Remedies"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "alert": "No Annual Results declared by Corona Remedies"
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
342.42
361.13
-5.18%
Operating Profit (PBDIT) excl Other Income
83.16
78.47
5.98%
Interest
1.66
1.93
-13.99%
Exceptional Items
-19.10
0.00
Standalone Net Profit
41.25
52.15
-20.90%
Operating Profit Margin (Excl OI)
24.29%
21.73%
2.56%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.18% vs 4.21% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.90% vs 12.39% in Sep 2025

stock-summaryCompany CV
About Corona Remedies Ltd stock-summary
stock-summary
Corona Remedies Ltd
Small Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available